Last reviewed · How we verify
NCT05928286
Observational Study of Efficiency of the Drug Remaxol® (Inosine + Meglumine + Methionine + Nicotinamide + Succinic Acid) Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
trial testing Remaxol in Gallstone Disease in 286 participants. Completed in 31 December 2025.
1 September 2025
Quick facts
| Lead sponsor | POLYSAN Scientific & Technological Pharmaceutical Company |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 286 |
| Start date | 1 December 2022 |
| Primary completion | 1 September 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 9 locations across Russia |
Drugs / interventions tested
- Remaxol — full drug profile →
Conditions studied
- Gallstone Disease — all drugs for Gallstone Disease →
- Obstructive Jaundice — all drugs for Obstructive Jaundice →
Sponsor
POLYSAN Scientific & Technological Pharmaceutical Company — full company profile →
Who can join
Adults 18 to 70, any sex, with Gallstone Disease or Obstructive Jaundice. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Therapy response rate: decrease of total bilirubin level down to 20.5 µmol/l Visit 3 or decrease in total bilirubin by 70% compared to Visit 1.
Time frame: Up to 2 weeks
Decrease of total bilirubin level down to 20.5 µmol/l Visit 3 or decrease in total bilirubin by 70% compared to Visit 1.
Sponsor's own description
Obstructive jaundice is observed in 10-80 % of gallstone disease cases. The conventional tactics for the management of patients with obstructive jaundice is to remove biliary hypertension by using endoscopic or minimally invasive methods. The final surgical treatment is performed after jaundice reduction and normalization of hepatic functions. We suppose that the administration of the drug Remaxol (Inosine + Meglumine + Methionine + Nicotinamide + Succinic acid) during the perioperative period shortens jaundice duration and decreases the complications rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05928286
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Remaxol
Trials testing the same drug.
- NCT06183242 — Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis · Phase 2, PHASE3 · completed
- NCT05789797 — Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy · completed
Other recruiting trials for Gallstone Disease
Currently open trials in the same condition.
- NCT07307703 — TENS for Anxiety, Pain, and Satisfaction After Laparoscopic Cholecystectomy · NA · recruiting
- NCT07421011 — Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 · Phase 1 · recruiting
- NCT06405906 — A Randomized Controlled Trial Comparing Fat-free Versus Balanced (WHO) Diet in Gallstone Disease · NA · recruiting
- NCT05689255 — Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions · recruiting
- NCT05618626 — Prevention of NAFLD and CVD Through Lifestyle Intervention · NA · recruiting
Other POLYSAN Scientific & Technological Pharmaceutical Company trials
Trials by the same sponsor.
- NCT06955416 — REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis · Phase 2, PHASE3 · recruiting
- NCT06514976 — Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy · recruiting
- NCT06735898 — Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tab · recruiting
- NCT06286254 — Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection · completed
- NCT06183229 — Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05928286 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by POLYSAN Scientific & Technological Pharmaceutical Company
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05928286.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing